
CDC Advisory Committee recommends Pfizer’s RSV vaccine
Betsy Goodfellow | September 25, 2023 | News story | Medical Communications | Abrysvo, Immunology, Pfizer, RSV
Pfizer has announced that the US Centers for Disease Control and Prevention’s (CDC) Advisory Committee on Immunization Practices (ACIP) has recommended Abrysvo, the company’s bivalent respiratory syncytial virus (RSV) vaccine, for maternal immunisation.
ACIP has recommended the jab as a maternal RSV vaccine for pregnant people from 32 to 36 weeks gestation, and using seasonal administration, to prevent RSV lower respiratory tract infections in infants.
The recommendation will become official once it is reviewed by the director of the CDC, and follows the US Food and Drug Administration’s (FDA) approval of the vaccine in August 2023.
Luis Jodar, PhD, chief medical affairs officer of Vaccines/Antivirals and Evidence Generation at Pfizer, commented: “This fall marks the start of the annual respiratory infection season in the Northern Hemisphere, and we are prepared with vaccines against multiple infectious diseases and – for the first time in history – an available RSV vaccine to help prevent disease in two at-risk populations. Today’s ACIP recommendation for maternal immunisation with Abrysvo reinforces the wide-ranging impact vaccines can have, including helping protect infants immediately at birth from the potentially severe and life-threatening complications that can develop from RSV. Approximately 75% of RSV-related hospitalisations in newborns and infants occur in the first six months of life.”Betsy Goodfellow
Related Content
NICE recommends Pfizer’s new once-weekly treatment for haemophilia B on NHS
Walton Oaks, 21st May 2025 – Pfizer Ltd announced today that the National Institute for Health and Care …

Pfizer releases results for severe RSV-associated LRTD treatment study
US-based Pfizer have announced results from its substudy B of the ongoing phase 3 clinical …
New Real-World Data Published in Journal of Cardiac Failure on Effectiveness
Patients treated with tafamidis were associated with greater rates of survival compared with patients untreated …






